|
|
Article: Mevacor(R) Reduces First Heart Attacks, Other Coronary Events by 36 Percent in Landmark Study of Healthy People
- Article from:
- PR Newswire
- Article date:
- November 12, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Trial Could Extend Benefits of Cholesterol-Lowering;
Strong Benefits Seen in Women and Elderly; Long-term Safety Reaffirmed
ORLANDO, Fla., Nov. 12 /PRNewswire/ -- The cholesterol-lowering drug Mevacor(R) (lovastatin, Merck & Co., Inc.) (NYSE: MRK) is the first statin to be found effective in preventing first coronary events, such as heart attack or unstable angina (chest pain), in healthy men and women with normal and near-normal cholesterol levels -- reducing such events by 36 percent -- according to preliminary results of a landmark study presented here at the American Heart Association Annual Scientific Sessions. The findings from ...